DT
DTIL.US Precision BioSciences Inc
- Market cap
- USD 289M
- P/E
- 31.5x
- P/B
- 5.93x
- ROE
- -151.1%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is DTIL.US undervalued?
Graham numberDTIL.US trades 188.2% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Precision BioSciences Inc fundamental analysis
No fundamental analysis for Precision BioSciences Inc yet.
Precision BioSciences Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Precision BioSciences Inc
Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing therapies for gene edits, including gene insertion, excision, and elimination in the United States. The company offers ARCUS, a genome editing platform for DNA genome insertion, removal, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits, as well as to inactivate inte…
Full company profilePrecision BioSciences Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Precision BioSciences Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 7.02M | 6.48M | 10.9M | 22.2M | 24.3M | 116M | 25.1M | 48.7M | 68.7M | 34.3M | 14.5M |
| Gross Profit | 7.02M | 6.48M | 10.9M | 22.2M | 24.3M | 116M | 25.1M | 48.7M | 68.7M | 34.3M | - |
| Operating Income | -8.83M | -22.0M | -47.9M | -87.2M | -110M | -39.4M | -62.3M | -43.7M | -26.2M | -52.1M | -64.9M |
| EBITDA | -8.19M | -20.4M | -43.7M | -87.4M | -99.2M | -20.3M | -62.8M | -32.0M | 13.5M | -42.4M | -92.1M |
| Net Income | -8.25M | -21.1M | -46.0M | -92.9M | -109M | -30.6M | -112M | -61.3M | 7.17M | -45.7M | -78.2M |
| EPS | -0.49 | -19 | -28 | -66 | -63 | -16 | -38 | -16 | 1.04 | -3.56 | -2.85 |
| Balance Sheet | |||||||||||
| Total Assets | 98.4M | 72.7M | 139M | 235M | 150M | 211M | 238M | 160M | 136M | 154M | 120M |
| Total Liabilities | 103M | 99.1M | 98.6M | 96.9M | 106M | 120M | 178M | 141M | 80.0M | 62.2M | 68.6M |
| Shareholders' Equity | -4.75M | -26.4M | 40.0M | 138M | 44.4M | 91.2M | 60.4M | 18.9M | 56.4M | 92.2M | 51.8M |
| Cash & Short-term Investments | 93.4M | 62.8M | 103M | 181M | 89.8M | 144M | 190M | 117M | 86.3M | 116M | 81.8M |
| Total Debt | - | - | - | - | 10.5M | 9.11M | 25.0M | 31.3M | 30.0M | 28.8M | 27.7M |
| Cash Flow | |||||||||||
| Operating Cash Flow | 92.3M | -24.2M | -51.7M | -73.6M | -87.4M | -10.9M | -45.8M | -84.1M | -58.4M | -65.8M | -54.0M |
| Capital Expenditure | 2.08M | 5.57M | 15.7M | 24.7M | 5.03M | 5.80M | 3.32M | 2.28M | 250K | 85.0K | 315K |
| Free Cash Flow | 90.2M | -29.7M | -67.4M | -98.3M | -92.4M | -16.7M | -49.1M | -86.4M | -58.7M | -65.9M | -54.0M |
| Ratios | |||||||||||
| ROE | - | - | -115.2% | -67.1% | -245.4% | -33.6% | -184.7% | -325.1% | 12.7% | -49.6% | -151.1% |
| ROA | -8.4% | -29.0% | -33.2% | -39.5% | -72.6% | -14.5% | -46.9% | -38.4% | 5.3% | -29.6% | -65.0% |
| Net Profit Margin | -117.6% | -325.4% | -423.0% | -417.6% | -448.9% | -26.5% | -444.8% | -125.8% | 10.4% | -133.4% | -541.4% |
| Debt to Equity | - | - | - | - | 0.24x | 0.10x | 0.41x | 1.66x | 0.53x | 0.31x | 0.54x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Precision BioSciences Inc dividends
Precision BioSciences Inc has not paid dividends in the last 9 fiscal years.
Last stock split: 1:30 on Feb 14, 2024.
Who owns Precision BioSciences Inc
- Insiders 5.82%
- Institutions 46.67%
- Public & others 47.51%
- Shares outstanding 38.2M
- Free float 26.4M
Top funds holding DTIL.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| abrdn World Healthcare | 1.14M | 4.10% | 0.00% | Sep 2026 |
| abrdn Life Sciences Investors | 1.09M | 3.89% | 0.00% | Sep 2026 |
| Vanguard MStar Total Stk Mkt Idx Invest | 778K | 2.79% | 0.00% | Sep 2026 |
| iShares Russell 2000 ETF | 587K | 2.10% | 0.00% | Oct 2026 |
| Meridian Contrarian Legacy | 454K | 1.63% | +65.66% | Sep 2026 |
| Fidelity Small Cap Index | 268K | 0.96% | +2.20% | Aug 2026 |
| iShares Russell 2000 Value ETF | 220K | 0.79% | 0.00% | Oct 2026 |
| Canada Life US Small-Mid Cap Growth F | 165K | 0.59% | -34.19% | Aug 2026 |
| Vanguard Russell 2000 ETF | 139K | 0.50% | +0.82% | Sep 2026 |
| Fidelity Extended Market Index | 129K | 0.46% | -0.38% | Sep 2026 |
| Fidelity Enhanced Small Cap Core ETF | 128K | 0.46% | +0.27% | Oct 2026 |
| iShares Micro-Cap ETF | 72.0K | 0.26% | 0.00% | Oct 2026 |
| Mackenzie GQE US Small Cap F8 | 62.2K | 0.22% | 0.00% | Aug 2026 |
| Schwab Small Cap Index | 58.3K | 0.21% | 0.00% | Sep 2026 |
| Jacob Discovery Fd Instl | 52.1K | 0.19% | +10.62% | Jun 2026 |
| IG Mackenzie GQE U.S. Sm Md Cap Eq C NL | 51.1K | 0.18% | 0.00% | Jul 2026 |
| Fidelity Total Market Index | 48.5K | 0.17% | -0.05% | Sep 2026 |
| iShares Russell 2000 Small-Cap Idx Instl | 44.8K | 0.16% | 0.00% | Sep 2026 |
| Russell Inv US Small Cap Equity Y | 40.9K | 0.15% | +80.19% | Sep 2026 |
| Fidelity VIP Disciplined Small Cap Init | 40.9K | 0.15% | +29.26% | Aug 2026 |
Top institutions holding DTIL.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Aberdeen Group PLC | 2.23M | 7.98% | 0.00% | Jun 2026 |
| Bleichroeder LP | 2.02M | 7.22% | +21.39% | Jun 2026 |
| Octagon Capital Advisors LP | 1.35M | 4.83% | -39.64% | Jun 2026 |
| BOOTHBAY FUND MANAGEMENT, LLC | 1.35M | 4.82% | +26.26% | Jun 2026 |
| BlackRock Inc | 1.17M | 4.20% | +487.14% | Jun 2026 |
| Vanguard Capital Management, LLC | 1.12M | 4.00% | +22.56% | Jun 2026 |
| Lynx1 Capital Management, LP | 950K | 3.40% | -3.52% | Jun 2026 |
| Driehaus Capital Management LLC | 947K | 3.39% | -4.89% | Jun 2026 |
| Empery Asset Management, LP | 776K | 2.78% | -60.58% | Jun 2026 |
| Affinity Asset Advisors, LLC | 647K | 2.31% | +8.13% | Jun 2026 |
| Geode Capital Management, LLC | 621K | 2.22% | +116.30% | Jun 2026 |
| Mackenzie Investments | 481K | 1.72% | 0.00% | Jun 2026 |
| State Street Corp | 427K | 1.53% | +485.84% | Jun 2026 |
| Acadian Asset Management LLC | 306K | 1.09% | +582.99% | Jun 2026 |
| ArrowMark Colorado Holdings, LLC (ArrowMark Partners) | 274K | 0.98% | +53.03% | Jun 2026 |
| CI Private Wealth LLC | 245K | 0.88% | +70.35% | Jun 2026 |
| Two Sigma Investments LLC | 238K | 0.85% | -22.72% | Jun 2026 |
| Northern Trust Corp | 190K | 0.68% | +150.02% | Jun 2026 |
| JPMorgan Chase & Co | 180K | 0.65% | +2,255,550.00% | Jun 2026 |
| Vanguard Fiduciary Trust Co | 167K | 0.60% | +7.01% | Jun 2026 |
Precision BioSciences Inc company profile
- Company name
- Precision BioSciences Inc
- Ticker
- DTIL.US
- Exchange
- USA Stocks
- Listed since
- Mar 28, 2019
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 69
- Fiscal year end
- December
- Address
- 302 East Pettigrew St., Durham, NC, United States, 27701
- Phone
- 919 314 5512
- Website
- precisionbiosciences.com
About Precision BioSciences Inc
Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing therapies for gene edits, including gene insertion, excision, and elimination in the United States. The company offers ARCUS, a genome editing platform for DNA genome insertion, removal, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits, as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; and PBGENE-DMD (Excision) for the treatment of Duchenne muscular dystrophy. In addition, the company develops PBGENE-3243 for the treatment of m.3243 associated mitochondrial diseases; and iECURE-OTC (Insertion) for ornithine transcarbamylase deficiency. It has collaboration agreements with TG Cell Therapy, Inc. to develop, manufacture, and commercialize azercabtagene zapreleucel for autoimmune diseases and other indications; and iECURE, Inc., an ARCUS-mediated targeted gene insertion. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.
Precision BioSciences Inc management
10- Mr. Michael AmorosoPresident, CEO & Director · born 1978
- Mr. John Alexander Kelly R.Ph.Chief Operating Officer · born 1967
- Mr. Dario Scimeca J.D.Chief Legal Officer & Secretary · born 1975
- Dr. Jefferson J. Smith Ph.D.Co-Founder & Chief Research Officer · born 1973
- Mr. Naresh TannaChief Financial Officer · born 1981
- Ms. Mei BurrisVP of Finance & Chief Accounting Officer · born 1986
- Dr. Cassie Gorsuch Ph.D.Chief Scientific Officer
- Ms. Juli BlancheChief People Officer
- Ms. Cindy AtwellChief Development Officer
- Mr. Neil Leatherbury M.S.Senior VP and Head of Chemistry, Manufacturing & Controls